InfuSystem Inc (INFU) - Multiplikator forward rega marang pendapatan

InfuSystem (INFU) - logo korporat

InfuSystem Holdings (INFU) relies on steady demand in oncology, which offsets the impact of macro shocks. High barriers to entry are created by complex accreditation processes and the inertia of equipment replacement in clinics. Risks are associated with the renegotiation of insurance contracts and the costs of fleet upgrades. The company's forward P/S reflects revenue valuation dynamics, where the 1.50 metric determines the parameter's status at the current stage.

INFU InfuSystem Holdings, Inc.: Multiplikator forward rega marang pendapatan ing interval 04.07.2022 - 13.11.2026

infusystem.com - rincian analitis lan metrik utama (INFU)

- indikator kapitalisasi pasar:
Analisis umum perusahaan:INFU (InfuSystem Inc)
Produk asli InfuSystem

For InfuSystem Holdings (INFU), whose value is based on the critical importance of oncology service maintenance, the forward P/S serves as an indicator of market expectations regarding future revenue. This metric compares current market capitalization with projected sales volume, allowing for an assessment of the cost of each unit of expected income. By analyzing the current forward P/S level, an investor can determine the premium the market assigns to seamless logistics and B2B trust from clinics.

Analisis perusahaan pesaing

Rasio rega marang prakiraan pendapatan Intuitive ISRG|Rega forward marang dodolan DHR|BDX: Multiplikator forward rega marang pendapatan|STE - Multiplikator Forward P/S|West Pharmaceutical Services (WST) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan baxter.com|MASI (Masimo) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stevanato Group SpA STVN|Rasio rega marang prakiraan pendapatan Teleflex Inc (TFX)|Merit Medical Corp - Kapitalisasi marang prakiraan pendapatan|Envista Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ICUI (icumed.com)|XRAY - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake LeMaitre Vascular Inc LMAT|ATRC: Multiplikator Forward P/S|STAA - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan ChromaDex Corporation|Kapitalisasi marang prakiraan pendapatan ZIMV (zimvie.com)|Multiplikator Forward P/S ANGO|CERS: Rega mangsa ngarep marang pendapatan|Alpha Teknova Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Monogram Orthopedics Inc. MGRM|STSS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake utahmed.com UTMD|KRMD (korumedical.com) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Nyxoah SA (NYXH)|Rasio rega marang prakiraan pendapatan Microbot Medical Inc|Pro-Dex Inc. (PDEX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan ZTEK (Zentek Ltd.)|Rasio rega marang pendapatan sing dikarepake ELUT|Multiplikator Forward P/S MLSS (Milestone Scientific Inc.)|NEXGEL Inc. (NXGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVP - Rasio rega marang prakiraan pendapatan|harvardbioscience.com (HBIO) - Multiplikator forward rega marang pendapatan|FEMY (Femasys Inc.) - Multiplikator forward rega marang pendapatan|Meihua Medical Technologies Co., Ltd. - Rega forward marang dodolan|POAI (Predictive Oncology Inc) - Multiplikator Forward P/S|CJMB: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Atrion Corp (ATRI)|NURO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep